TORONTO, CANADA, June 15, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (the “Company”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on…

Term Sheet Signed to License Healthcare Intellectual Property to UK Healthcare Consortium Exclusively in the UK Market Strategic Review of Norwegian Healthcare Clinics Business Unit Initiated TORONTO, CANADA, June 9,…

Annual Revenue Increased by 534% TORONTO, CANADA, April 28, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing therapeutics to treat addiction with a…

TORONTO, CANADA, April 26, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (the “Company”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol…

Phase III Trial will Assess Ketamine-Assisted Therapy for The Treatment of Severe Alcohol Use Disorder TORONTO, CANADA, 18 April, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a…

TORONTO, CANADA, April 12, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use…

Partnership is Awakn’s first with a dedicated addiction treatment clinic, Ken Starr MD Wellness Group TORONTO, CANADA, Feb 28, 2023 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a…

Awakn Will License its Protocols for Treating Addiction and Mental Health to a Healthcare Consortium to Help Accelerate Their Development of a Chain of Clinics in Portugal TORONTO, CANADA, Feb…

Awakn Clinics Trondheim is its second clinic in Norway TORONTO, CANADA, Feb 14, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to…

TORONTO, CANADA, February 9, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol…

Designation Aims to Accelerate Time to Market TORONTO, CANADA, February 7, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company developing therapeutics to treat addiction…

Study Has Potential to Lead to In-Licensing Agreement and Accelerated Pathway to Phase II TORONTO, CANADA, January 24, 2023 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”),…